Qiagen N.V. (QGEN): Among the Cash-Rich Mid Cap Stocks to Buy Now
We recently compiled a list of the 10 Cash-Rich Mid Cap Stocks To Buy Now. In this article, we are going to take a look at ...
Business Wire29d
QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region
fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products ...
Le Lézard8d
iSON Xperiences and Aistra Announce Strategic Partnership to Drive AI-Powered CX Transformation
SON Xperiences, a global leader in AI-driven customer experience (CX) solutions with a presence in 22 countries, has announced a strategic partnership with Aistra, an AI Adoption company, focusing on ...
Le Lézard15d
Softchoice Commits $900,000 of In-kind Technology Support for TakingITGlobal
Through the partnership, Softchoice will contribute up to $900,000 of in-kind services over 3 years to help TakingITGlobal increase the ... iSON Xperiences, a global leader in AI-driven customer ...
PharmiWeb4d
Artificial Intelligence in Precision Medicine Global Market Sales Volume, Growth Rate Trend Research Report 2025-2034
The latest research report published by Vantage Market Research, titled "An Increase in Demand and Opportunities for the ...
eLife11d
A dual ribosomal system in the zebrafish soma and germline
Shah and colleagues take advantage of the presence of maternal and somatic ribosomes in zebrafish and confirm their differential expression during development. The authors convincingly show that ...
EuropaWire7d
QIAGEN Gains FDA Approval for New QIAstat-Dx Gastrointestinal Panel 2 Mini B, Expanding Syndromic Testing Options
QIAGEN has received FDA approval for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its syndromic testing offerings for gastrointestin ...
Business Wire11d
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A.
Qiagen files patent infringement complaint against bioMerieux
Qiagen (QGEN) announced that it has filed a complaint against bioMerieux for patent infringement. The complaint, filed in the Local Division of ...
TMCnet8d
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further ...
Nasdaq11d
QIAGEN Files Patent Complaint Against BioMérieux To Protect QuantiFERON Technology
(RTTNews) - QIAGEN N.V. (QGEN) announced that it has filed a complaint against bioMrieux S.A. for patent infringement, reinforcing its commitment to protecting the scientific advancements behind ...
Morningstar11d
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products ...